MGMT and glioblastoma: To determine if the observed heterogeneity was a direct consequence of established molecular subtypes in GBM, we performed cross-platform analyses using RNA (expression profiling) and DNA (IDH1 mutation and MGMT promoter methylation) isolated from matched tumor tissue.